Single Mutations in HIV Integrase Confer High-Level Resistance to Raltegravir in Primary Human Macrophages

Identification and Characterization of Persistent Intracellular Human Immunodeficiency Virus Type 1 Integrase Strand Transfer Inhibitor Activity

(2010) Yasuhiro Koh et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Total Raltegravir Concentrations in Cerebrospinal Fluid Exceed the 50-Percent Inhibitory Concentration for Wild-Type HIV-1

(2010) D. Croteau et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Cross-Resistance Profile Determination of Two Second-Generation HIV-1 Integrase Inhibitors Using a Panel of Recombinant Viruses Derived from Raltegravir-Treated Clinical Isolates

(2010) L. Van Wesenbeeck et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Plasma and Intracellular (Peripheral Blood Mononuclear Cells) Pharmacokinetics of Once-Daily Raltegravir (800 Milligrams) in HIV-Infected Patients

(2010) José Moltó et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Evaluation of HIV-1 integrase inhibitors on human primary macrophages using a luciferase-based single-cycle phenotypic assay

(2010) Zuleika Michelini et al.   JOURNAL OF VIROLOGICAL METHODS

Identification of Novel Mutations Responsible for Resistance to MK-2048, a Second-Generation HIV-1 Integrase Inhibitor

(2010) T. Bar-Magen et al.   JOURNAL OF VIROLOGY

Primary mutations selected in vitro with raltegravir confer large fold changes in susceptibility to first-generation integrase inhibitors, but minor fold changes to inhibitors with second-generation resistance profiles

(2010) Olivia Goethals et al.   VIROLOGY

Resistance to Integrase Inhibitors

(2010) Mathieu Métifiot et al.   Viruses-Basel

The dynamics of appearance and disappearance of HIV-1 integrase mutations during and after withdrawal of raltegravir therapy

(2009) Ruth Bridget Ferns et al.   AIDS

Loss of Raltegravir Susceptibility by Human Immunodeficiency Virus Type 1 Is Conferred via Multiple Nonoverlapping Genetic Pathways

(2009) S. Fransen et al.   JOURNAL OF VIROLOGY

Selective-Advantage Profile of Human Immunodeficiency Virus Type 1 Integrase Mutants Explains In Vivo Evolution of Raltegravir Resistance Genotypes

(2009) R. Quercia et al.   JOURNAL OF VIROLOGY

The G140S mutation in HIV integrases from raltegravir-resistant patients rescues catalytic defect due to the resistance Q148H mutation

(2009) O. Delelis et al.   NUCLEIC ACIDS RESEARCH

Raltegravir Cerebrospinal Fluid Concentrations in HIV-1 Infection

(2009) Aylin Yilmaz et al.   PLoS One

Mutations Associated with Failure of Raltegravir Treatment Affect Integrase Sensitivity to the Inhibitor In Vitro

(2008) I. Malet et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Subgroup and Resistance Analyses of Raltegravir for Resistant HIV-1 Infection

(2008) David A. Cooper et al.   NEW ENGLAND JOURNAL OF MEDICINE

Decay dynamics of HIV-1 depend on the inhibited stages of the viral life cycle

(2008) A. R. Sedaghat et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA